Senzime outlicenses ExSpiron in the Chinese market
Uppsala, June 19, 2023. Senzime AB (publ), a leader in the field of peri- and post-operative patient monitoring solutions, has today entered into an exclusive license agreement with the Chinese company CoreSpiron (Henan) Co Ltd. The agreement grants CoreSpiron up to 10 years of manufacturing and sales rights for Senzime’s ExSpiron system in the Chinese market… ExSpiron is part of the product portfolio of Respiratory Motion Inc., which Senzime acquired in 2022. The product is based on clinical research and innovations by cardiothoracic surgeon Dr. Jenny Freeman. Read more >>